{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for pantothenic root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:trazpiroben [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03644264: Phase 3 Interventional Completed Chronic Kidney Disease Requiring Chronic Dialysis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Mevinic acid is reversible competitive inhibitors of HMG-CoA reductase (Ki in the range of 0.2-1 nM). Mevinic acid is a precursor of a Mevastatin (mevinic acid lactone) -- a hypolipidemic agent that belongs to the statins class. Mevastatin inactive until metabolized in the liver to the open-ring hydroxy acid (Mevinic acid). Mevastatin might be considered the first statin drug; clinical trials on mevastatin were performed in the late 1970s in Japan, but it was never marketed.
Status:
Investigational
Source:
NCT04022785: Phase 1 Interventional Completed Acute Myeloid Leukemia
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00329368: Phase 1 Interventional Completed Cancer
(2005)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
INN:zorifertinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
AZD-3759 is an oral inhibitor of both wild-type and mutant EGFR with IC50 values in nanomolar range. The drug was discovered by AstraZeneca for the treatment of non-small-cell lung cancer with CNS metastases. AZD-3759 can penetrate the blood-brain barrier and was confirmed to be effective in vitro with NSCLC cell lines as well as in mouse model of brain metastases. AZD-3759 is currently in Phase 1 clinical trial.
Status:
Investigational
Source:
NCT04308954: Phase 1 Interventional Terminated Fragile X Syndrome (FXS)
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00751803: Phase 2 Interventional Completed Migraine Disorders
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
BI 44370 was developed as a calcitonin gene-related peptide receptor antagonist for the treatment of acute migraine attacks. In spite of the positive results from the phase II clinical trials, the BI-44370 study has been discontinued.
Status:
Investigational
Source:
NCT00533650: Phase 2 Interventional Completed Post-Menopausal Osteoporosis
(2000)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
